EMEA workshop on Monoclonal Antibodies

Date: 02/07/2009
Location: London
The EMEA workshop on biosimilar monoclonal antibodies (mAbs) was intended to discuss the feasibility of the scientific development and authorisation of monoclonal antibodies via the European biosimilar regulatory pathways. 159 people including health care professionals, academics, representatives from regulatory agencies in the European Union (EU), United States (US) and Canada, and 40 biopharmaceutical companies located worldwide attended the workshop. Participation was by invitation only.

Documents

How useful was this page?

Add your rating